Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy

被引：0

作者：

Brandes, V ^{[1
]}

Scheffler, M. ^{[1
]}

Kambartel, K. ^{[2
]}

Ortiz-Cuaran, S. ^{[3
]}

Scheel, A. ^{[4
]}

Michels, S. ^{[5
]}

Nogova, L. ^{[5
]}

Fischer, R. ^{[5
]}

Abdulla, D. ^{[5
]}

Merkelbach-Bruse, S. ^{[4
]}

Buettner, R. ^{[4
]}

Sos, M. L. ^{[3
]}

Wolf, J. ^{[5
]}

机构：

[1] Uniklin Koln, Innere Med Klin 1, Lung Canc Grp Cologne, Cologne, Germany

[2] Krankenhaus Bethanien, Moers, Germany

[3] Uniklin Koln, Dept Translat Genom, Cologne, Germany

[4] Uniklin Koln, Inst Pathol, Cologne, Germany

[5] Uniklin Koln, Innere Med Klin 1, Cologne, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P568

引用

页码：172 / 172

页数：1

共 50 条

[1] EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
Wang, Zhulin
Huang, Chunyao
Fan, Wenbo
Sun, Shaowu
Li, Kaiyuan
Liu, Xu
Pu, Jiangtao
Zhang, Guoqing
Li, Xiangnan
[J]. FRONTIERS IN ONCOLOGY, 2024, 14
[2] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
Gan, Jiadi
Huang, Yihua
Liao, Jun
Pang, Lanlan
Fang, Wenfeng
[J]. ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
[3] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wenxian Wang
Hong Wang
Peihua Lu
Zongyang Yu
Chunwei Xu
Wu Zhuang
Zhengbo Song
[J]. Journal of Translational Medicine, 17
[4] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wang, Wenxian
Wang, Hong
Lu, Peihua
Yu, Zongyang
Xu, Chunwei
Zhuang, Wu
Song, Zhengbo
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
[5] The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
Wang, Yubo
Tian, Panwen
Xia, Lei
Li, Li
Han, Rui
Zhu, Mengxiao
Lizaso, Analyn
Qin, Tian
Li, Min
Yu, Bing
Mao, Xinru
Han Han-Zhang
He, Yong
[J]. LUNG CANCER, 2020, 146 : 165 - 173
[6] Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
Zhuang, W.
Xu, C.
Wang, W.
Song, Z.
Zhu, Y.
Chen, R.
Guan, Y.
Yi, X.
Fang, M.
Chen, G.
Lv, T.
Song, Y.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[7] Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy
Lee, J. H.
Ahn, B.
Kim, M. H.
Pyo, K.
Lee, C.
Lim, S. M.
Hong, M. H.
Kim, H. R.
Cho, B. C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1145 - S1146
[8] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Yamaoka, Toshimitsu
Ohmori, Tohru
Ohba, Motoi
Arata, Satoru
Kishino, Yasunari
Murata, Yasunori
Kusumoto, Sojiro
Ishida, Hiroo
Shirai, Takao
Hirose, Takashi
Ohnishi, Tsukasa
Sasaki, Yasutsuna
[J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
[9] Retreatment with EGFR-TKI for 541 NSCLC Patients with EGFR Mutation
Takahashi, K.
Ito, K.
Murotani, K.
Asada, K.
Okuno, M.
Kimura, T.
Kubo, A.
Suda, T.
Taniguchi, H.
Hataji, O.
Shindo, J.
Kunii, E.
Yoshida, T.
Imaizumi, K.
Hida, T.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S833 - S833
[10] Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes
Tsai, J. S.
Lin, C. -Y.
Su, P. L.
Lin, C. -C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S602 - S602

← 1 2 3 4 5 →